{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:03:01Z","timestamp":1789776181443,"version":"4.0.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100008660","name":"Kurozumi Medical Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008660","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010655","name":"Tokai University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["24590709"],"award-info":[{"award-number":["24590709"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.leukres.2015.09.009","type":"journal-article","created":{"date-parts":[[2015,9,12]],"date-time":"2015-09-12T11:24:19Z","timestamp":1442057059000},"page":"1405-1413","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["FLT3-ITD drives Ara-C resistance in leukemic cells via the induction of RUNX3"],"prefix":"10.1016","volume":"39","author":[{"given":"Anar","family":"Damdinsuren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satomi","family":"Asai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Miyachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2015.09.009_bib0005","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1182\/blood-2005-01-0178","article-title":"Drug therapy for acute myeloid leukemia","volume":"106","author":"Tallman","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.09.009_bib0010","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","article-title":"The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The medical research council adult and children\u2019s leukaemia working parties","volume":"92","author":"Grimwade","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.09.009_bib0015","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1182\/asheducation-2009.1.385","article-title":"Independent prognostic factors for AML outcome. Hematology\/the Education Program of the American Society of Hematology","author":"Grimwade","year":"2009","journal-title":"Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.leukres.2015.09.009_bib0020","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.1158\/1078-0432.CCR-12-0313","article-title":"New strategies in acute myeloid leukemia: redefining prognostic markers to guide therapy","volume":"18","author":"Khan","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2015.09.009_bib0025","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2015.09.009_bib0030","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1182\/blood-2013-01-451781","article-title":"Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia","volume":"121","author":"Abdel-Wahab","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.09.009_bib0035","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1532\/IJH97.05066","article-title":"Clinical significance of FLT3 in leukemia","volume":"82","author":"Kiyoi","year":"2005","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.leukres.2015.09.009_bib0040","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1182\/asheducation-2006.1.178","article-title":"FLT3 mutations: biology and treatment. Hematology\/the Education Program of the American Society of Hematology","author":"Small","year":"2006","journal-title":"Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.leukres.2015.09.009_bib0045","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.leukres.2009.10.001","article-title":"Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse","volume":"34","author":"Ravandi","year":"2010","journal-title":"Leukemia Res."},{"key":"10.1016\/j.leukres.2015.09.009_bib0050","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2010-08-301796","article-title":"Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse","volume":"117","author":"Levis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.09.009_bib0055","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.1158\/1078-0432.CCR-08-1123","article-title":"Structural and functional alterations of FLT3 in acute myeloid leukemia","volume":"15","author":"Meshinchi","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2015.09.009_bib0060","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1038\/leu.2012.114","article-title":"Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia","volume":"26","author":"Swords","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2015.09.009_bib0065","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.bbrc.2009.10.094","article-title":"FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression","volume":"390","author":"Jin","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.leukres.2015.09.009_bib0070","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1038\/sj.leu.2400768","article-title":"Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23)","volume":"11","author":"Matsuo","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2015.09.009_bib0075","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.celrep.2014.06.046","article-title":"Disruption of Runx1 and Runx3 leads to bone marrow failure and leukemia predisposition due to transcriptional and DNA repair defects","volume":"8","author":"Wang","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.leukres.2015.09.009_bib0080","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ng1285","article-title":"Complete sequencing and characterization of 21,243 full-length human cDNAs","volume":"36","author":"Ota","year":"2004","journal-title":"Nat. Genet."},{"key":"10.1016\/j.leukres.2015.09.009_bib0085","doi-asserted-by":"crossref","first-page":"e111082","DOI":"10.1371\/journal.pone.0111082","article-title":"Establishment of a humanized APL model via the transplantation of PML-RARA-Transduced human common myeloid progenitors into immunodeficient mice","volume":"9","author":"Matsushita","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2015.09.009_bib0090","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/(SICI)1097-0215(19990702)82:1<63::AID-IJC12>3.0.CO;2-2","article-title":"Microsatellite instability and clonal heterogeneity of MDR1 messenger RNA expression in trimetrexate-resistant human leukemia MOLT-3 cells developed in thymidine","volume":"82","author":"Miyachi","year":"1999","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.leukres.2015.09.009_bib0095","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2008-02-137083","article-title":"Transcriptional repression of the RUNX3\/AML2 gene by the t(8;21) and inv(16) fusion proteins in acute myeloid leukemia","volume":"112","author":"Cheng","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.09.009_bib0100","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1182\/blood-2003-12-4449","article-title":"Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes","volume":"104","author":"Lacayo","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.09.009_bib0105","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.leukres.2011.08.006","article-title":"High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia","volume":"35","author":"Kuhnl","year":"2011","journal-title":"Leukemia Res."},{"key":"10.1016\/j.leukres.2015.09.009_bib0110","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1182\/blood-2009-09-241943","article-title":"High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemia","volume":"115","author":"Kuhnl","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.09.009_bib0115","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1046\/j.1365-2141.2002.03637.x","article-title":"The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells","volume":"118","author":"Konopleva","year":"2002","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2015.09.009_bib0120","first-page":"607","article-title":"The chronic myelocytic cell line K562 contains a breakpoint in bcr and produces a chimeric bcr\/c-abl transcript","volume":"6","author":"Grosveld","year":"1986","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.leukres.2015.09.009_bib0125","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/sj.leu.2402740","article-title":"FLT3 mutations in acute myeloid leukemia cell lines","volume":"17","author":"Quentmeier","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2015.09.009_bib0130","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S1079-9796(03)00031-7","article-title":"The Runx genes as dominant oncogenes","volume":"30","author":"Cameron","year":"2003","journal-title":"Blood cells, Mol. Dis."},{"key":"10.1016\/j.leukres.2015.09.009_bib0135","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nrc1607","article-title":"The RUNX genes. gain or loss of function in cancer","volume":"5","author":"Blyth","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.leukres.2015.09.009_bib0140","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0378-1119(01)00760-0","article-title":"The RUNX3 gene-sequence, structure and regulated expression","volume":"279","author":"Bangsow","year":"2001","journal-title":"Gene"},{"key":"10.1016\/j.leukres.2015.09.009_bib0145","doi-asserted-by":"crossref","first-page":"6512","DOI":"10.1158\/0008-5472.CAN-06-0369","article-title":"RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer","volume":"66","author":"Lau","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2015.09.009_bib0150","first-page":"411","article-title":"RUNX3 gene promoter demethylation by 5-Aza-CdR induces apoptosis in breast cancer MCF-7 cell line","volume":"6","author":"Kang","year":"2013","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.leukres.2015.09.009_bib0155","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1158\/0008-5472.CAN-09-3805","article-title":"Role of RUNX3 in bone morphogenetic protein signaling in colorectal cancer","volume":"70","author":"Lee","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2015.09.009_bib0160","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ygyno.2011.04.044","article-title":"RUNX3 functions as an oncogene in ovarian cancer","volume":"122","author":"Lee","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.leukres.2015.09.009_bib0165","doi-asserted-by":"crossref","first-page":"7646","DOI":"10.1038\/sj.onc.1209739","article-title":"RUNX3 protein is overexpressed in human basal cell carcinomas","volume":"25","author":"Salto-Tellez","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2015.09.009_bib0170","doi-asserted-by":"crossref","first-page":"e5892","DOI":"10.1371\/journal.pone.0005892","article-title":"RUNX3 has an oncogenic role in head and neck cancer","volume":"4","author":"Tsunematsu","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2015.09.009_bib0175","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1182\/blood-2012-10-460618","article-title":"Runx3 deficiency results in myeloproliferative disorder in aged mice","volume":"122","author":"Wang","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.09.009_bib0180","first-page":"2140","article-title":"Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells","volume":"9","author":"Spiekermann","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2015.09.009_bib0185","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1182\/blood-2007-10-121426","article-title":"Anchoring of FLT3 in the endoplasmic reticulum alters signaling quality","volume":"113","author":"Schmidt-Arras","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.09.009_bib0190","doi-asserted-by":"crossref","first-page":"e74653","DOI":"10.1371\/journal.pone.0074653","article-title":"Pim-1 kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplication","volume":"8","author":"Natarajan","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2015.09.009_bib0195","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1158\/0008-5472.CAN-05-2309","article-title":"Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR\/ABL","volume":"66","author":"Adam","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2015.09.009_bib0200","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1182\/blood-2008-11-188714","article-title":"Survivin mediates aberrant hematopoietic progenitor cell proliferation and acute leukemia in mice induced by internal tandem duplication of Flt3","volume":"114","author":"Fukuda","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.09.009_bib0205","doi-asserted-by":"crossref","first-page":"e19798","DOI":"10.1371\/journal.pone.0019798","article-title":"PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy","volume":"6","author":"Zhou","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2015.09.009_bib0210","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.stem.2014.08.001","article-title":"SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells","volume":"15","author":"Li","year":"2014","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.leukres.2015.09.009_bib0215","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0959-437X(03)00007-8","article-title":"RUNX transcription factors as key targets of TGF-beta superfamily signaling","volume":"13","author":"Ito","year":"2003","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.leukres.2015.09.009_bib0220","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1365-2141.2008.07130.x","article-title":"TGF-beta receptor kinase inhibitor LY2109761 reverses the anti-apoptotic effects of TGF-beta1 in myelo-monocytic leukaemic cells co-cultured with stromal cells","volume":"142","author":"Xu","year":"2008","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2015.09.009_bib0225","doi-asserted-by":"crossref","first-page":"e62785","DOI":"10.1371\/journal.pone.0062785","article-title":"TGF-beta-neutralizing antibody 1D11 enhances cytarabine-induced apoptosis in AML cells in the bone marrow microenvironment","volume":"8","author":"Tabe","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2015.09.009_bib0230","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1038\/bcj.2012.5","article-title":"Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies","volume":"2","author":"Kasper","year":"2012","journal-title":"Blood Cancer J."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261530374X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261530374X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,26]],"date-time":"2022-06-26T00:17:43Z","timestamp":1656202663000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521261530374X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":46,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S014521261530374X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2015.09.009","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FLT3-ITD drives Ara-C resistance in leukemic cells via the induction of RUNX3","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2015.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}